FIELD: biotechnology.
SUBSTANCE: described is use of peptide containing a domain similar to epidermal growth factor (EGF-like), in producing a pharmaceutical composition for reducing side effects caused by supraphysiological levels of the peptide, after administration in treating or preventing cardiac failure in a mammal for a long time, wherein said EGF-like domain is an EGF-like domain of glia growth factor 2 (GGF2), and wherein a therapeutically effective amount of said peptide is administered to a mammal at least 96 hours apart for treating or preventing cardiac failure in said mammal.
EFFECT: invention extends the range of products for treating cardiac failure in mammals; according to the invention, a therapeutic effect of neuregulin, such as glia growth factor 2 (GGF2) or its fragment, is preserved and / or improved with minimizing any potential side effects.
10 cl, 15 dwg, 11 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| NUCLEOTIDE SEQUENCE ENCODING FUSED PROTEIN CONSISTING OF SOLUBLE EXTRACELLULAR FRAGMENT OF HUMAN Dll4 AND CONSTANT PART OF HEAVY CHAIN OF HUMAN IgG4 | 2021 |
|
RU2787060C1 |
| DISPLAY OF AN INTEGRAL MEMBRANE PROTEIN ON EXTRACELLULAR ENVELOPED POXVIRUS VIRIONS | 2017 |
|
RU2759846C2 |
| THERAPEUTIC FUSION PROTEINS | 2020 |
|
RU2825292C1 |
| METHODS OF TREATING TISSUE CALCIFICATION | 2015 |
|
RU2770698C2 |
| COMPOSITION FOR PREVENTION AND TREATMENT OF SKIN DISEASE CONTAINING SUBSTANCE SPECIFICALLY BINDING WITH VIMENTINE DERIVATIVE PEPTIDE | 2018 |
|
RU2751486C1 |
| ANTI-PCSK9 ANTIBODY, ITS ANTIGEN-BINDING DOMAIN AND MEDICAL APPLICATION THEREOF | 2016 |
|
RU2739208C2 |
| FUSED MOLECULES DERIVED FROM CHOLIX-TOXIN FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE LOADS | 2015 |
|
RU2723178C2 |
| MODIFIED NON-NATURAL NKG2D LIGANDS WHICH SELECTIVELY DELIVER ATTACHED HETEROLOGOUS MOLECULES TO NON-NATURAL NKG2D RECEPTORS ON CAR CELLS | 2020 |
|
RU2823728C2 |
| TGFβR2 MOLECULE WITH TRUNCATED EXTRACELLULAR DOMAIN, FUSION PROTEIN OF TGFβR2 MOLECULE WITH TRUNCATED EXTRACELLULAR DOMAIN, AND ANTI-EGFR ANTIBODIES, AND ANTI-TUMOUR USE OF FUSED PROTEIN | 2021 |
|
RU2824199C1 |
| STABILIZED F RSV PROTEINS AND THEIR USE | 2019 |
|
RU2795459C2 |
